Buyout of Genoptix Prompts Shareholder Claims Investigation by Goldfarb Branham Law Firm LLP
25 Enero 2011 - 12:50PM
Business Wire
Goldfarb Branham LLP is investigating whether the board of
Genoptix, Inc. (Nasdaq:GXDX) violated shareholder protection laws
in connection with the proposed acquisition by Novartis for $25.00
per share. If you are a Genoptix shareholder or have information
about this transaction, contact the firm at 877-583-2855 or by
email at hlindley@goldfarbbranham.com.
“This offer represents a 27% premium over Genoptix’s Friday
closing price of $19.76,” said securities lawyer Hamilton Lindley.
“Analysts have set a high price target $28.00 per share for
Genoptix and it traded for $38 per share in May 2010. Also, as part
of the deal, management has secured positions for themselves in the
going forward company.”
Goldfarb Branham’s lawyers have significant experience
representing individual and institutional investors in over 100
shareholder class action cases. A firm securities lawyer, Hamilton
Lindley, can be reached at hlindley@goldfarbbranham.com or
877-583-2855 to discuss the impact of this buyout on Genoptix
shareholders.
Genoptix, Inc. (MM) (NASDAQ:GXDX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Genoptix, Inc. (MM) (NASDAQ:GXDX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Genoptix, Inc. (MM) (NASDAQ): 0 recent articles
Más de Goldfarb Branham LLP Artículos de Noticias